Skip to main content
. 2023 Dec 9;14:8161. doi: 10.1038/s41467-023-43937-1

Fig. 4. Adjunctive PARP inhibition reduces TB lung inflammation.

Fig. 4

Lung histopathology of M.tb-infected female C3HeB/FeJ mice (implantation: 111 ± 9 CFU) 3 months post infection following 2 months of treatment with PZA (150 mg/kg), talazoparib (Tp; 0.5 mg/kg) or vehicle (1.97% DMSO in 0.5% CMC), alone or in combination with RIF (10 mg/kg). a Schematic overview. b Lung bacterial burden at the end of treatment. n = 8 (Tp), 10 (vehicle, RIF, RIF + PZA) or 11 (PZA, RIF + Tp). Statistical differences were determined by one-way ANOVA with Šidák’s multiple comparisons test. **p = 0.0067; ***p = 0.0006; ****p < 0.0001. c Representative H&E-stained lung sections. d–f Quantified areas of lung inflammation (d), % lung involvement (e), or quantified vimentin-positive area indicative of fibroblasts expressed as a percent of total lung area (f). Each symbol represents an individual mouse, with mean ± SEM indicated. n = 2 (Tp) or 3 (all other groups). Statistical differences were determined by one-way ANOVA with uncorrected Fisher’s LSD test (d, e) or Dunnett’s multiple comparisons test (f) with a single pooled variance. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; exact p values are provided in the Source Data file. Histopathology and IHC analyses were performed on randomized and coded slides by a veterinary pathologist blinded to experimental design. Adjunctive PARP inhibition reduced lung inflammation independently of bacterial burden. Source data are provided as a Source Data file.